Biotech M&A – 2022 Deals

Biotech M&A – 2022 Deals

Biotech M&A With a Slow Start in 2022: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/19/2022UCB, Brussels, BelgiumUCBZogenix ZGNX$1.9B$26.00$2 CVR, Epilepsy drug
02/14/2022Collegium PharmaceuticalCOLLBioDelivery Sciences BDSI$604M$5.60Pain Portfolio
04/07/2022PfizerPFEReViralPrivate$525M-Antiviral targeting RSV- respiratory syncytial virus
04/13/2022GlaxoSmithKlineGSKSierra OncologySRRA$1.9B$55.00Momelotinib potential of myelofibrosis patients with anaemia
04/13/2022HalozymeHALOAntares PharmaATRS$960M$5.60auto injector platform
04/19/2022RegeneronRGENCheckmate PharmaceuticalsCMPI$250M$10.50 vidutolimod, CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist
05/10/2022PfizerPFEBiohaven PharmaceuticalBHVN $11.6B$148.50Plus 0.5 of a share of a new publicly traded company that retains Biohaven’s non-CGRP pipeline compounds
06/03/2022Bristol Myers SquibbBMYTurning Point TherapeuticsTPTX$4.1B$76.00ROS1/NTRK Inhibitor for ROS1-positive First-Line NSCLC
06/23/2022invoX Pharma - UKINVOXF-star TherapeuticsFSTX$161M$7.12bispecific antibody platform
06/23/2022Gurnet Point CapitalPrivateRadius HealthRDUS$890M$10.00CVR $1.00
06/27/2022IpsenIPSEYEpizymeEPZM$247M$1.45CVR $1.00 achievement of $250M net sales of Tazverik
07/11/2022InnovivaINVALa Jolla PharmaceuticalLJPC$149M$5.95and an incremental $0.28/shr for the divestiture of a non-core asset
07/11/2022VertexVRTXViaCytePrivate$320M-Stem-Cell VX-880 Programs in Type 1 Diabetes
07/25/2022Ginkgo BioworksDNAZymergenZY$300M~$2.680.9179 Ginkgo shares for each Zymergen share (~$2.92)
08/04/2022AmgenAMGNChemoCentryx, IncCCXI$3.7B$52TAVNEOS® for Patients With Serious Autoimmune Disease
08/04/2022GileadGILDMiroBioPrivate$405M-Pipeline of Immune Checkpoint Agonists
08/08/2022PfizerPFEGlobal Blood Therapeutics GBT$5.4B$68.50sickle cell disease (SCD)

For M&A 2021 full table click here

Recent Press


Log In

JoinLost Password?